Prime Medicine (NasdaqGM:PRME) FY Conference October 21, 2025 08:45 AM ET Company ParticipantsAllan Reine - CEODevyn Smith - CEOGilmore O'Neill - CEOEmma Wang - Co-founder and CTOTian Zhu - Co-founder and CEOConference Call ParticipantsGula Lifshitz - Biotech AnalystGula LifshitzFor the morning. Maybe let's start there. Welcome to Chardan's ninth annual Genetic Medicines Conference. Before we begin, let me share the compliance statement. It covers the presentations today. Our conference presenters have atte ...

NEW YORK, Oct. 07, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, announced today that findings highlighting the strong potential of circular single-stranded DNA (CssDNA) as a universal, efficient non-viral template for gene therapy, along with a comprehensive study of TALE base editors (TALEB) off-targets in the nuclear genome, will b ...